Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS: Momelotinib in VEXAS Syndrome
NCT07569081Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of mivavotinib in VEXAS syndrome (VEXAS), sponsored by GSK. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
mivavotinib
03
Conditions
VEXAS syndrome (VEXAS)
Beyond the preview
Go deeper on NCT07569081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07569081.